Novel food : The regulation authorizing the tetrahydrocurcuminoids C3 Reduct® has been published today, with validation of the 5 years protection

Novel food : The regulation authorizing the tetrahydrocurcuminoids C3 Reduct® has been published today, with validation of the 5 years protection

Curcumin C3 Reduct® is the hydrogenated derivative of the natural curcuminoids from Curcumin C3 Complex®, allowing to bring directly the active metabolites. After the positive opinion by EFSA on very last end of December, the authorization has just been published today in the official journal. Our C3 Reduct® by Sabinsa can so be lawfully on the market within 20 days.

It was speculated that the therapeutic effectiveness of Curcumin is limited due to its poor absorption in the body. Indeed, oral doses of Curcumin result in only traces appearing in the blood. In the last decade, much of the focus has been on enhancing  the absorption of Curcumin, for instance using the natural bioenhancer, Bioperine®.

  • Curcumin converts enzymatically into THC inside the intestine
  • C3 Reduct allows to bring directly the metabolite, whatever is the inter individual metabolism
One of the most important breakthroughs in the understanding of Curcumin in metabolism, was the discovery of its reductive metabolites in intestinal and hepatic cytosol in humans and rats : the major biliary metabolite of Curcumin discovered in the rat was Tetrahydrocurcumin. Study found that E. coli, a commensal microorganism had the highest Curcumin converting activity in the human intestine. And researchers were also able to isolate and purify the enzyme  from E. Coli involved in Curcumin conversion and named it CurA (NADPH- dependent curcumin/dihydrocurcumin  reductase). Curcumin is metabolized to DHC and then THC

See the publication : here


In the last decade, THC, the major component in C3 Reduct® has gone through evaluation for  several pharmacological activities confirming its  position as the most important metabolite of Curcumin, but also  as a possible solution for overcoming the perceived   bioavailability problems associated with Curcumin.

Curcumin C3 Reduct® is the hydrogenated derivative of the curcuminoids from Curcumin C3 Complex®. It contains a minimum of 95% of Tetrahydrocurcuminoids (THCs) namely Tetrahydrocurcumin (THC), Tetrahydrodemethoxycurcumin (THDMC) and Tetrahydrobisdemethoxycurcumin (THBDMC). It is colourless, tasteless and aesthetically acceptable than curcuminoids (which gives yellow stain).

Curcumin and THC are the major constituents (≥ 75% of the total content) of the turmeric and reduced (hydrogenated) turmeric preparations, respectively. Tetrahydrocurcumin has higher physiological and pharmacological activities than its parent compound. The therapeutic interest for THC lies in its low toxicity and its beneficial biological activities

Keeping in pace with the developing science on the turmeric and its active compounds, Sabinsa presents you the next generation of curcuminoids as Curcumin C3 Reduct®.

  • Curcumin C3 Reduct® has a better absorption profile in intestine than the parent curcuminoids
  • Curcumin C3 Reduct® has a better stability at physiological pH
  • Tetrahydrocurcuminoids (THCs) present in the Curcumin C3 Reduct® are pharmacologically active form
  • The THCs present in Curcumin C3 Reduct® has shown stronger biological activities than parent curcuminoids themselves
  • Curcumin C3 Reduct® due to its nonstaining nature can also be used in oral hygiene products such as toothpaste, dental creams or washes
  • The difference in metabolism between individuals is not an issue anymore
  • It is a stain free
  • It is white in color
  • It has better pH stability and hence provides more flexibility in formulations
  • It can be formulated into tablets, capsules, soft gels, gummies, and powdered premix dosages as well as into beverage